The U.S. "stem cell clinic" landscape.
Americans imagine "stem cell therapy in the U.S." as something rare, maybe academic, maybe FDA-approved. The reality is that there are roughly eleven hundred stem-cell clinics operating in this country, almost none of which culture cells, and the gap between what they say and what they do is the whole reason the FDA exists.
Prefer to watch?
Why almost none of them grow cells.
Short on time? The video walks the same landscape: how many U.S. clinics there really are, what they actually do, and the gap between the two. Keep scrolling for the full version.
operating today
under §361
More "stem-cell clinics" than any other country, by a factor of five, almost none of them actually culture cells.
- 01 ~1,100 clinics, almost all under §361. Up from ~570 in 2016. The FDA's "same-day autologous" loophole: no IND filed, no agency review, is where the entire commercial industry lives.
- 02 Not cultured cells. "Stem cells" in a U.S. clinic almost always means SVF (fat), BMC (marrow), PRP, or amniotic / umbilical lyophilized product. None are FDA-approved for any condition outside the licensed hematopoietic indications.
- 03 FL, CA, TX hold ~40%. Three states concentrate the industry, driven by retiree density and state-level enforcement laxity. The rest tail off quickly.
- 04 FDA enforcement is selective. Two landmark precedents confirm culturing without an IND is illegal: US Stem Cell (2019) and California Stem Cell (Ninth Circuit 2024, finalized by SCOTUS cert denial in 2025). Day-of, autologous, minimally-manipulated products remain technically legal, which is why every clinic markets exactly that.
- 05 Not actually cheap. Once you bundle work-up, injection, and follow-ups it adds up. And the cells themselves are usually a small fraction of what a properly cultured, dose-characterized infusion delivers.
Active clinics, 2024
~1,100
Up from ~570 in 2016. The U.S. has more "stem-cell clinics" than any other country in the world by a factor of 5.
Operating under §361
~97%
Same-day autologous "homologous use". the FDA loophole that lets a clinic offer "stem cell therapy" with no IND filed.
Active U.S. INDs for MSC therapy
~110
The number of trial programs running the legitimate §351 path. These are trials, not commercial therapies.
FDA injunctions, 2017–2025
5
Plus ~80 untitled letters and warning letters. The enforcement footprint is small relative to the industry size.
A sea of clay. If you walked into a U.S. stem-cell clinic at random, you have about a 96.8% chance of being offered same-day SVF, BMC, PRP, or amniotic product. Not cultured cells. The blue and red dots are statistical noise against the §361 mainstream. Hover the grid to find them.
FDA enforcement actions, despite making headlines, have not slowed the industry. The two injunctions marked on the chart (2017 framework, 2019 US Stem Cell) saw the growth curve continue straight through them; the 2024 Ninth Circuit ruling in the California Stem Cell case and the 2025 SCOTUS cert denial extend the same precedent without changing the trajectory. Selective enforcement against a few egregious actors leaves the §361 mainstream undisturbed.
What "stem cell therapy in the U.S." actually means, depending on the clinic.
Every U.S. operator falls into one of three lanes. The patient rarely knows which one their clinic is in: but the lane is what determines whether you're getting a real cellular product, a placebo-grade injection, or a federal-investigation candidate.
Section 361 / "homologous use"
Same-day, autologous, "minimally manipulated". the loophole. No IND, no FDA review.
Section 351 / IND-filed
Cultured, expanded, or allogeneic MSCs under an active FDA Investigational New Drug application, i.e. a clinical trial.
Operating in violation
Clinics that culture or market cells as drugs without an IND. The category FDA injunctions and warning letters target.
The shorthand: Lane 1 is where almost everyone goes, Lane 2 is what most people think they're going to, and Lane 3 is what the FDA shuts down when it gets around to it. The marketing for all three sounds similar.
The product menu under the §361 loophole.
The legal products available at a typical U.S. stem-cell clinic, compared to what an actual cultured cGMP MSC infusion delivers. The semantic distance between "stem cell therapy" as marketed and "MSC therapy" as practiced internationally is wide.
* "§361 legal" requires minimal manipulation, homologous use, autologous or first/second-degree relative, and not combined with another article. Almost every U.S. clinic's marketing implies cellular activity that the §361 path doesn't actually permit them to claim. The FDA's tolerance of this messaging gap is the entire reason the industry exists at its current size.
"Our stem cell injection delivers millions of regenerative cells."
Total nucleated cells, mostly immune cells and RBCs. The actual MSC count is rarely disclosed, and is typically 10k–500k, not millions.
"FDA-registered facility."
"Registered" is an administrative listing for tissue establishments. It is not FDA approval, FDA inspection, or FDA clearance. Any clinic can register a facility in 24 hours by filing a form.
"We use the same cells that hospitals use in clinical trials."
Almost never true. Trial-grade MSCs are cultured §351 products manufactured under IND. A §361 clinic legally cannot use that product. The cells in the clinic are minimally-manipulated autologous SVF or BMC.
"Treats arthritis, neuropathy, MS, autoimmune conditions, and more."
FDA does not authorize the product for any of these. "Off-label" injections occur, but disease-specific advertising is the most common FDA-warning-letter trigger.
"Umbilical-derived stem cells, donated from healthy mothers."
Almost always lyophilized (freeze-dried) amniotic-fluid product. Lyophilization destroys live cells. What you receive is growth-factor cocktail in saline, not live MSCs.
Four operators run about a third of the U.S. industry.
Most U.S. clinics are independent. But a handful of networks have built nationwide footprints and represent the most professional end of the §361 mainstream. They are not equivalent: physician training, protocols, and transparency all differ, but they share the lane.
The legitimate §351 path costs a fortune and eight years. The §361 loophole costs an LLC filing and a centrifuge. Guess which one the industry chose.
Selective, slow, but real.
The FDA's posture on §361 vs §351 has hardened steadily since 2017, but the agency has chosen specific test cases rather than a categorical sweep. These are the moments that shaped the current landscape.
"FDA Framework" guidance issued
Clarified what counts as "minimal manipulation" and "homologous use." Gave the industry a 3-year grace period to comply.
Three Florida patients go blind
US Stem Cell Inc., intravitreal SVF injection for macular degeneration. Triggered the first FDA injunction.
US Stem Cell injunction
First permanent injunction. Court rules SVF, when expanded or used non-homologously, is a drug requiring IND. The legal precedent.
California Stem Cell trial
District court rules against FDA in the California Stem Cell Treatment Center case. Brief moment of legal cover for the SVF industry.
Ninth Circuit reverses
Appeals court sides with FDA. SVF prepared by enzymatic digestion is more-than-minimal manipulation; the §361 carve-out does not apply. The clearest precedent the agency now has.
Untitled-letter wave
~25 untitled letters issued to clinics marketing amniotic / umbilical products with disease claims. No clinic closures yet.
SCOTUS denies cert
The Supreme Court declines to take the California Stem Cell appeal. The Ninth Circuit ruling stands. The final word on SVF as a drug.
A U.S. clinic product is not the same thing as a cultured-MSC infusion, whatever the headline numbers suggest.
The mental shortcut that treats a U.S. clinic and a cultured-MSC program as the same purchase at different rates misses what you're buying. U.S. products are almost universally same-day cell mixtures with low MSC content. A cultured, characterized MSC infusion delivers far more MSCs per dose. Comparing the two on the rate alone, rather than on what is actually in the syringe, is the central error.
The U.S. has more "stem-cell clinics" than anywhere on earth. and almost none of them deliver what their marketing implies.
This is the central confusion behind why patients fly to Mexico. The 1,100 U.S. clinics are not analogues of a cultured-MSC program, they're operating in a different regulatory lane with a different product. They are not bad medicine in many cases; many are good orthopedic practices doing legitimate PRP and BMC injections. They are just not, in any meaningful sense, "stem cell therapy" as the international cell-therapy field uses the term.
If you understand that, the rest of the geography makes sense. The U.S. has thousands of clinics offering small-volume autologous biologics. Mexico has dozens of clinics offering cultured cGMP MSCs at international standard of care. Those are not competitors. They are different industries with overlapping marketing.